Impact of Juglone, a PIN1 İnhibitor, on Oral Carcinogenesis Induced by 4-Nitroquinoline-1-Oxide (4NQO) in Rat Model
Olgun Topal1, Burcu Güçyetmez Topal2, Yunus Baş1
1Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Afyonkarahisar Health Sciences University, 03200 Afyonkarahisar, Turkey.
Abstract:
Background and Objectives: PIN1 is overexpressed in several human cancers, including prostate cancer, breast cancer, and oral squamous carcinomas. Juglone (J), derived from walnut, was reported to selectively inhibit PIN1 by modifying its sulfhydryl groups. In this study, the potential effects of juglone, also known as PIN1 inhibitor, on oral cancer and carcinogenesis were investigated at the molecular level. Materials and Methods: 4-Nitroquinoline N-oxide (4-NQO) was used to create an oral cancer model in animals. Wistar rats were divided into five groups: Control, NQO, Juglone, NQO+J, and NQO+J*. The control group received the basal diet and tap water throughout the experiment. The NQO group received 4-NQO for 8 weeks in drinking water only. The Juglone group was administered intraperitoneally in a juglone solution for 10 weeks (1 mg/kg/day). The NQO+J group received 4-NQO in drinking water for 8 weeks, starting 1 week after the cessation of 4-NQO treatment. They were then administered intraperitoneally in a juglone solution for 10 weeks. (1 mg/kg/day). NQO+J* group: received 4 NQO for 8 weeks in drinking water and administered intraperitoneally in a juglone solution for 10 weeks (1 mg/kg/day). They were sacrificed at the end of the 22-week experimental period. The tongue tissues of the rats were isolated after the experiment, morphological changes were investigated by histological examinations, and the molecular apoptotic process was investigated by rt-qPCR and western blot. Results: Histological results indicate that tumors are formed in the tongue tissue with 4-NQO, and juglone treatment largely corrects the epithelial changes that developed with 4-NQO. It has been determined that apoptotic factors p53, Bax, and caspases are induced by the effect of juglone, while antiapoptotic factors such as Bcl-2 are suppressed. However, it was observed that the positive effects were more pronounced in rats given juglone together with 4-NQO. Conclusions: The use of PIN1 inhibitors such as juglone in place of existing therapeutic approaches might be a promising and novel approach to the preservation and treatment of oral cancer and carcinogenesis. However, further research is required to investigate the practical application of such inhibitors.
Insights
Juglone, a PIN1 inhibitor, shows promise in treating oral cancer by correcting epithelial changes and inducing apoptosis. Combined treatment with juglone and 4-NQO yielded the most significant positive effects in rats.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Peptidyl-prolyl cis-trans isomerase (PIN1) is overexpressed in various human cancers, including oral squamous cell carcinomas.
- Juglone, a natural compound derived from walnut, selectively inhibits PIN1 by modifying its sulfhydryl groups.
Purpose of the Study:
- To investigate the potential effects of juglone as a PIN1 inhibitor on oral cancer and carcinogenesis at the molecular level.
- To evaluate juglone's efficacy in an animal model of oral cancer induced by 4-Nitroquinoline N-oxide (4-NQO).
Main Methods:
- An oral cancer model was established in Wistar rats using 4-NQO.
- Rats were divided into five groups: Control, 4-NQO, Juglone, 4-NQO+Juglone, and 4-NQO+Juglone*.
- Tumorigenesis and apoptotic pathways were analyzed using histological examinations, rt-qPCR, and Western blot.
Main Results:
- 4-NQO induced tumor formation and epithelial changes in rat tongue tissues.
- Juglone treatment largely corrected these epithelial changes and induced apoptosis by upregulating p53, Bax, and caspases while downregulating Bcl-2.
- The combined administration of juglone with 4-NQO demonstrated more pronounced positive effects.
Conclusions:
- Juglone, as a PIN1 inhibitor, represents a novel and promising therapeutic strategy for oral cancer and carcinogenesis.
- Further research is warranted to explore the practical clinical applications of juglone in oral cancer treatment.


